Novo Nordisk A/S (NVO)
| Market Cap | 163.11B -58.5% |
| Revenue (ttm) | 48.59B +6.4% |
| Net Income | 16.10B +1.4% |
| EPS | 3.62 +1.8% |
| Shares Out | 4.47B |
| PE Ratio | 10.13 |
| Forward PE | 11.36 |
| Dividend | $1.23 (3.37%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 26,364,029 |
| Open | 36.49 |
| Previous Close | 37.08 |
| Day's Range | 36.18 - 37.00 |
| 52-Week Range | 35.85 - 81.44 |
| Beta | 0.27 |
| Analysts | Hold |
| Price Target | 51.00 (+39.61%) |
| Earnings Date | May 6, 2026 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for NVO stock is "Hold." The 12-month stock price target is $51.0, which is an increase of 39.61% from the latest price.
News
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?
Novo Nordisk unveiled a troubling guidance for 2026, which tanked the stock. It recently reached a deal with telehealth company Hims & Hers Health to sell its GLP-1 products.
Novo Nordisk (NVO) Faces Generic Competition in India as Key Patent Expires
Novo Nordisk (NVO) Faces Generic Competition in India as Key Patent Expires
Novo Nordisk (NVO) GLP-1 Medications Linked to Increased Cardiovascular Risks
Novo Nordisk (NVO) GLP-1 Medications Linked to Increased Cardiovascular Risks
Novo Nordisk Expands Obesity Drug Offerings with FDA Approval
Novo Nordisk Expands Obesity Drug Offerings with FDA Approval
China expresses hopes over Novo Nordisk's presence in market
China hopes Novo Nordisk will "continue to cultivate the Chinese market and contribute to building a healthy China," said Ling Ji, China's vice commerce minister, during a meeting with an ...
The Dow's losing streak, fertilizer prices, Novo Nordisk's new Wegovy shot and more in Morning Squawk
Here are five key things investors need to know to start the trading day.
India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry
The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how gener...
India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry
The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how gener...
Novo Nordisk Wins FDA Approval For Higher-Dose Wegovy HD, Delivering 20.7% Weight Loss
(RTTNews) - Novo Nordisk (NVO) announced that the FDA has approved Wegovy HD (semaglutide 7.2 mg), a higher-dose, once-weekly injectable version of its blockbuster obesity drug Wegovy, offering patien...
Market Today: Big Banks, Novo Nordisk, Tesla in Focus
Market Today: Big Banks, Novo Nordisk, Tesla in Focus
Novo Nordisk (NVO) Gains FDA Approval for New High-Dose Wegovy
Novo Nordisk (NVO) Gains FDA Approval for New High-Dose Wegovy
A high dose of Wegovy helped people lose 21% of their weight. It was just approved.
Novo Nordisk's 7.2 mg dose of Wegovy will compete against Lilly's GLP-1 injection.
FDA approves higher dose of Wegovy
The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, Novo Nordisk, increased the semaglutide injection by 4.8 mg to total 7.2 mg....
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
• Novo Nordisk shares are experiencing downward pressure. What's pulling NVO shares down?
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy
The U.S. Food and Drug Administration (FDA) on Thursday approved a higher-dose version of Novo Nordisk A/S’ (NYSE: NVO) blockbuster weight-loss drug, Wegovy, marking an expansion of its treatment por...
Novo Nordisk (NVO) Gains FDA Approval for New Weight Loss Drug
Novo Nordisk (NVO) Gains FDA Approval for New Weight Loss Drug
Novo Nordisk's Higher Dose Wegovy Weight-Loss Drug Gains U.S. Approval
The Danish drugmaker said the accelerated approval was based on results from its Step Up trial, which showed 20.7% mean weight loss for participants with obesity.
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The Food and Drug Administration approved a higher dose version of Novo Nordisk's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from Eli Lilly. The high-dose...
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment* with Wegovy ® HD (~19% regardless of whether patients stayed on treatment**) in the STEP UP trial1 I...
FDA approves Novo Nordisk's new Wegovy® HD injection, delivering the highest weight loss to date for a Wegovy® injection, adding to its already expansive clinical profile
Average weight loss of ~21% at 72 weeks in adults with obesity if all patients stayed on treatment * with Wegovy ® HD (~19% regardless of whether patients stayed on treatment **) in the STEP UP trial...
US FDA approves higher dose of Wegovy
Novo Nordisk said on Thursday the U.S. Food and Drug Administration has approved a high dose of Wegovy to reduce excess body weight and maintain weight reduction long term.
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
Wegovy® HD demonstrated a mean weight loss of 20.7%1, and around one-third of patients achieved 25% or greater weight loss in the STEP UP trial First US FDA approval of a GLP-1 treatment under the Com...
A ₹1500 weight loss drug? The opportunity and the danger for India
The expiry of Novo Nordisk’s patent on semaglutide in India marks a watershed moment in the country’s pharmaceutical and public health landscape. As the active ingredient behind globally dominant drug...
1 Reason I'm Never Selling Novo Nordisk Stock
Novo Nordisk has been a leader in its core market for decades. This grants the pharmaceutical giant several advantages.